Shekher Bose: Asundexian’s Targeted Factor XIa Inhibition May Transform Secondary Stroke Prevention Strategies
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence’s post on LinkedIn, adding:
”Asundexian’s targeted Factor XIa inhibition offers potent antithrombotic protection with a differentiated safety profile (minimal impact on hemostasis), potentially transforming care for millions worldwide and could pave the way for broader, safer secondary stroke prevention strategies—if approved.”
Quoting Beyondsight Intelligence‘s post:
”Bayer’s Asundexian Cuts Stroke Risk by 26%, No increase in major bleeding in Phase 3
Bayer reported positive topline results from the Phase 3 OCEANIC-STROKE trial evaluating asundexian (50 mg), an investigational once-daily oral Factor XIa inhibitor.
Key Highlights:
• 26% reduction in recurrent stroke risk vs placebo
• Studied in patients with prior non-cardioembolic ischemic stroke or high-risk TIA
• Added on top of standard antiplatelet therapy
• No increase in ISTH major bleeding vs placebo
• Designed for effective thrombosis prevention with a wider safety margin
Why It Matters:
• Current antithrombotics often require a trade-off between efficacy and bleeding risk
• Factor XI inhibition is emerging as a next-generation anticoagulation strategy
• Could enable safer long-term secondary stroke prevention
Key Takeaway:
Asundexian’s Phase 3 results suggest meaningful stroke risk reduction without the usual bleeding penalty—potentially reshaping the future of antithrombotic therapy.
Follow our page for more such updates.
News Source Demonstrated a Substantial Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers